🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

FINALLY - what I have been looking forward to prove for 20 years: the detection performance of DRE for PCa is so weak that we can forego this exam. Hope the guidelines take this evidence to stop recommending DRE for PCa screening/early detection. sciencedirect.com/science/articl…

Really interesting new data on PCa screening #EAU24 Re-Imagine trial Caroline Moore shows many PCa in men < 3 ng/mL but Göteborg-2 trial shows possible overdiagnosis in 1.8-3 ng/mL European Urology. PRAISE-U and Organized Prostate Testing programs will provide more data. Praise_U

See this article to understand better the need for early detection in prostate cancer: theparliamentmagazine.eu/news/article/p…

Last week at #EAU24, I had the privilege to present on intermediate endpoints at the #EBM session. We also presented our study on oncologic surveillance following surgery for #kidneycancer. The study was selected as one of the best presentations at the conference #EAU24.

How can we reduce morbidity after robot-assisted radical cystectomy with intracorporeal neobladder? A report on postoperative complications by the European Association of Urology (EAU) ERUS Robotic Urology Working Group Alberto Martini Laura S. Mertens Carlo Andrea Bravi Alex Mottrie Juhana Rautiola doi.org/10.1111/bju.16…

Sharing our study on disease trajectory among men with HR localized #ProstateCancer treated with RP or RT from the PC database Sweden ▶️10% of men overall died from PC in 10 years post diagnosis ▶️1/3 of men who received secondary ADT died from PC 10 years after ADT BJU International

Congrats to our fellow Sunny Nalavenkata and mentor Sigrid Carlsson for their best poster on prostate cancer screening decision aids! #aua24

Now published in NEJM Evidence by UrologyMSK Sigrid Carlsson et al.: Prostate cancer foundation screening guidelines for black men in the United states evidence.nejm.org/doi/full/10.10…

🏁first meeting in 2024 for Yau PCa in Paris at #EAU24. Proud of our Chair @giorgiogandaglia recieving the Crystal Matula Award! 🏆 🤗Welcome to new members! Looking forward to achieve more and more as a Group!

Extremely proud and honored to be part of this amazing group. Eager to learn from amazing mentors Giorgio Gandaglia

Now published in JAMA by UrologyMSK Hans Lilja et al.: Prostate cancer screening with PSA, kallikrein panel, and MRI: The ProScreen randomized trial jamanetwork.com/journals/jama/…

Another great achievement from the VCORE superstar fellow Shane Tinsley!!! A step towards understanding, fighting and overcoming racial disparity in prostate cancer outcomes

The EMA has approved Enfortumab Vedotin and pembrolizumab for 1st line urothelial cancer. It supersedes 1st platinum based therapy as the new standard of care in Europe. astellas.com/en/news/29371?…

Cancer prevention and control improvements can significantly reduce the cancer burden. Tobacco control, better screening uptake, and addressing modifiable risks are key. Investment in new preventive agents and tech is crucial. #cancer #oncology OncoAlert @AmerCancerCEO

Cancer Statistics 2025 are out! #prostatecancer incidence still on the rise, mortality basically flat. Get screened so you can get treatment _when needed_. #pcsm acsjournals.onlinelibrary.wiley.com/doi/epdf/10.33…

Comparing #EMBARK vs EAU high-risk biochemical recurrence criteria in #ProstateCancer. Ugo_Falagario Karolinska Institutet sits down with Zach Klaassen Georgia Cancer Center to discuss findings from an analysis of the Stockholm-0 database comparing EAU high-risk and EMBARK criteria

Valiant effort Ugo_Falagario to revisit the question of BCR definition comparability for RP vs. RT for #prostatecancer. Closest seems to be nadir + 0.5 for RT vs. >0.5 with PSADT <9mos for RP. I still personally want CSM outcomes for CER studies, but this is very helpful. #AUA25

Comparing #EMBARK vs EAU high-risk biochemical recurrence criteria in #ProstateCancer. Ugo_Falagario Karolinska Institutet sits down with Zach Klaassen Georgia Cancer Center to discuss findings from an analysis of the Stockholm-0 database comparing EAU high-risk and EMBARK criteria

PEACE-3: Enzalutamide + Radium-223 improved rPFS (19.4 vs 16.4 mo) and OS (42.3 vs 35.0 mo) in mCRPC with bone mets. ⚠️Fracture risk ⬆️ BUT mandatory bone-targeting agents ⬇️ it. tombal silke gillessen Advanced Prostate Cancer Consensus Conference ESMO - Eur. Oncology Annals of Oncology OncoAlert

🚨Epidemiology of High-risk Biochemical Recurrence After Primary #ProstateCancer Treatment🚨 🙍‍♂️🙍‍♂️17K population-based study 👉 Using BCR risk groups continues to show promise to personalize treatment intensity for future patients European Urology Oncology 🔗shorturl.at/LuvYZ